22:38:48 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2023-11-28 15-6 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-29 Kvartalsrapport 2023-Q2
2023-06-14 Ordinarie utdelning EMPLI 0.00 SEK
2023-06-13 Årsstämma 2023
2023-05-12 Kvartalsrapport 2023-Q1
2023-05-02 Extra Bolagsstämma 2023
2023-02-23 Bokslutskommuniké 2022
2022-11-17 Kvartalsrapport 2022-Q3
2022-11-14 Extra Bolagsstämma 2022
2022-08-18 Kvartalsrapport 2022-Q2
2022-04-26 Kvartalsrapport 2022-Q1
2022-04-07 Ordinarie utdelning EMPLI 0.00 SEK
2022-04-06 Årsstämma 2022
2022-02-22 Bokslutskommuniké 2021
2021-11-19 Kvartalsrapport 2021-Q3
2021-08-20 Kvartalsrapport 2021-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriLäkemedel & Handel
Emplicure utvecklar produkter baserat på kombinationen av redan godkända aktiva substanser och materialvetenskap inom biokeramer, med skräddarsydda frisättningsprofiler som specialitet. Moderbolaget fokuserar på läkemedel, initialt mot kronisk smärta och med egenskaper som motverkar att de kan missbrukas. Via dotterbolag utvecklas konsumentprodukter, med oralt nikotin som första produktlinje. Sortimenten riktar sig till läkemedels- och konsumentnischer.
2022-09-19 12:26:18

Uppsala 2022-09-19 Emplicure AB (publ) announces today that the Company's Board of Directors has resolved to appoint member of the board and co-founder Håkan Engqvist as new CEO and President. 

As a result of the by the Company developments, Emplicure now moves into a new phase regarding both product development and commercialization. As such, the Board of Directors today resolved to appoint member of the board and co-founder Håkan Engqvist as new CEO and President. Torbjörn Walker Larsson will remain on the Group's ongoing projects for some time.

"With broad background from academic research in the field of bioceramics, experience of development from the Sandvik Group, and more than 15 years in early-stage development companies in operational as well as board roles, Håkan becomes a natural link bridging the group's operations," says Gisela Sitbon, Chairman of the Board of Emplicure.

"I look forward to driving both the product development and the commercialization of the company's products. In particular, Amplicon's nicotine pouches, with their interesting release profiles for flavour and nicotine, are in a good position to go to market within the coming year," says Håkan Engqvist.

In addition to his position as CEO, Håkan will retain his professorship at Uppsala University.

"I want to thank Torbjörn for his efforts for the company. He has done a creditable job in leading Emplicure through the IPO of the company's shares on Nasdaq First North Growth Market in Stockholm and has continued to strengthen the company's organization and structure to enable the further development of the company's product candidates," says Gisela Sitbon, Chairman of the Board of Emplicure.

Facts about Håkan Engqvist: Håkan holds a Ph.D. and is a Professor in Applied Materials Science at Uppsala University. He has extensive experience in research and development of bioceramics and of operational roles as well as board work in the medtech industry. Håkan has founded several companies, including Ossdsign AB, Psilox AB and Emplicure AB. Member of the board of Emplicure AB since 2015. 

This information is information that Emplicure AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The informationen was submitted for publication, through the agency of the contact persons above, on September 19, 2022 at 12:20 CET.

Adviser
Certified Adviser is Mangold Fondkommission AB
For more information, please contact:

Gisela Sitbon
Chairman of the Board
Phone: +46 (0)70 282 55 58
Email: gisela@sitbon.nu

Erik Magnusson
CFO, Investor Relations
Phone: +46 (0)708 565 245
Email: erik.magnusson@emplicure.com

The following documents can be retrieved from beQuoted
PM-Hakan-Engqvist-new-CEO-of-Emplicure.pdf

Emplicure develops new and innovative products by combining existing and approved active substances with advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain and on abuse-deterrent formulations. Wholly owned subsidiary Amplicon AB develops consumer products with oral nicotine as the first product. The share is listed on Nasdaq First North Growth Market (EMPLI). Read more at www.emplicure.com